CMAX · Caremax, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $198.63M | $232.25M | - | $201.84M | $224.44M | $172.98M | - | $157.67M | $172.28M | $27.92M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | $351.37M | $253.95M | - | $292.62M | $228.19M | $281.61M | - | $166.22M | $178.77M | $147.81M |
| D&A | $6.51M | $6.71M | - | $6.83M | $6.83M | $6.58M | - | $4.57M | $4.90M | $514.0K |
| Operating Income | ($152.74M) | ($21.70M) | - | ($90.77M) | ($3.75M) | ($108.62M) | - | ($8.55M) | ($6.49M) | ($10.89M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $177.0K | $177.0K | - | $177.0K | $177.0K | $177.0K | - | $181.0K | $171.0K | $181.0K |
| Net Income | ($170.56M) | ($43.41M) | - | ($103.12M) | ($32.38M) | ($82.08M) | - | ($22.05M) | ($9.38M) | ($16.80M) |
| EPS - Basic | ($44.79) | ($11.49) | - | ($0.92) | ($0.29) | ($0.74) | - | ($0.25) | ($0.11) | $0.12 |
| EPS - Diluted | ($44.79) | ($11.49) | - | ($0.92) | ($0.29) | ($0.74) | - | ($0.25) | ($0.11) | ($0.19) |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.43M | $41.48M | $65.53M | $32.26M | $54.60M | $44.22M | $41.63M | $53.31M | $68.13M | $32.74M |
| Accounts Receivable | $97.49M | $107.98M | $114.75M | $139.57M | $159.81M | $158.99M | $151.04M | $85.77M | $72.63M | $53.58M |
| Inventory | - | - | - | - | - | - | $723.0K | $911.0K | $915.0K | $702.0K |
| Accounts Payable | $8.45M | $6.70M | $6.28M | $9.35M | $8.68M | $8.13M | $7.69M | $13.42M | $9.16M | $5.17M |
| Current Assets | $123.47M | $156.11M | $183.35M | $176.66M | $218.65M | $210.00M | $197.34M | $162.18M | $164.35M | $107.72M |
| Total Assets | $454.04M | $614.20M | $623.30M | $1.06B | $1.15B | $1.10B | $1.17B | $707.43M | $708.98M | $649.09M |
| Current Liabilities | $529.67M | $507.11M | $438.81M | $98.34M | $98.07M | $80.43M | $77.32M | $33.74M | $27.11M | $28.14M |
| Long-term Debt | $1.78M | $1.88M | $21.44M | $302.61M | $298.48M | $260.64M | $230.72M | $184.25M | $181.50M | $109.66M |
| Total Liabilities | $601.80M | $593.80M | $561.86M | $533.50M | $526.47M | $557.94M | $551.20M | $238.23M | $220.85M | $156.90M |
| Stockholders' Equity | ($147.76M) | $20.40M | $61.44M | $524.62M | $624.50M | $539.76M | $619.55M | $469.20M | $488.13M | $492.19M |
| Retained Earnings | ($934.90M) | ($764.35M) | ($720.94M) | ($255.17M) | ($152.05M) | ($119.67M) | ($37.59M) | ($48.20M) | ($26.14M) | ($16.76M) |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($23.80M) | - | - | - | ($21.75M) | - | - | - | ($12.14M) |
| Investing Cash Flow | - | ($126.0K) | - | - | - | ($2.29M) | - | - | - | ($1.69M) |
| Financing Cash Flow | - | ($119.0K) | - | - | - | $26.63M | - | - | - | ($1.57M) |
| CapEx | - | $126.0K | - | - | - | $2.29M | - | - | - | $1.69M |
| Free Cash Flow | - | ($23.93M) | - | - | - | ($24.03M) | - | - | - | ($13.83M) |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -76.9% | -9.3% | - | -45.0% | -1.7% | -62.8% | - | -5.4% | -3.8% | -39.0% |
| EBITDA margin | -73.6% | -6.5% | - | -41.6% | 1.4% | -59.0% | - | -2.5% | -0.9% | -37.2% |
| Net margin | -85.9% | -18.7% | - | -51.1% | -14.4% | -47.5% | - | -14.0% | -5.4% | -60.2% |
| Free cash flow margin | - | -10.3% | - | - | - | -13.9% | - | - | - | -49.5% |
| FCF / Net income | - | 0.55 | - | - | - | 0.29 | - | - | - | 0.82 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -37.6% | -7.1% | - | -9.7% | -2.8% | -7.5% | - | -3.1% | -1.3% | -2.6% |
| Return on equity | 115.4% | -212.8% | - | -19.7% | -5.2% | -15.2% | - | -4.7% | -1.9% | -3.4% |
| Return on invested capital | - | -77.0% | - | -8.7% | -0.3% | -10.7% | - | -1.0% | -0.8% | -1.4% |
| Liquidity | ||||||||||
| Current ratio | 0.23 | 0.31 | 0.42 | 1.80 | 2.23 | 2.61 | 2.55 | 4.81 | 6.06 | 3.83 |
| Quick ratio | 0.23 | 0.31 | 0.42 | 1.80 | 2.23 | 2.61 | 2.54 | 4.78 | 6.03 | 3.80 |
| Cash ratio | 0.03 | 0.08 | 0.15 | 0.33 | 0.56 | 0.55 | 0.54 | 1.58 | 2.51 | 1.16 |
| Leverage | ||||||||||
| Debt / Equity | -0.01 | 0.09 | 0.35 | 0.58 | 0.48 | 0.48 | 0.37 | 0.39 | 0.37 | 0.22 |
| Debt / Assets | 0.00 | 0.00 | 0.03 | 0.29 | 0.26 | 0.24 | 0.20 | 0.26 | 0.26 | 0.17 |
| Debt / EBITDA | - | - | - | - | 96.97 | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -3.07 | 30.10 | 10.14 | 2.02 | 1.84 | 2.03 | 1.89 | 1.51 | 1.45 | 1.32 |
| Liabilities / Assets | 1.33 | 0.97 | 0.90 | 0.50 | 0.46 | 0.51 | 0.47 | 0.34 | 0.31 | 0.24 |
| Efficiency | ||||||||||
| Asset turnover | 0.44 | 0.38 | - | 0.19 | 0.20 | 0.16 | - | 0.22 | 0.24 | 0.04 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 179d | 170d | - | 252d | 260d | 335d | - | 199d | 154d | 701d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -11.5% | 34.3% | - | 28.0% | 30.3% | 519.6% | - | 50.7% | 283.5% | - |
| Revenue CAGR (3y) | 64.1% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -3973.1% | 80.0% | - | -961.4% | 42.2% | -897.5% | - | 23.8% | 33.3% | -575.5% |
| Net income growth (YoY) | -426.8% | 47.1% | - | -367.6% | -245.1% | -388.7% | - | -672.7% | - | - |
| EPS growth (YoY) | -15344.8% | -1452.7% | - | -268.0% | -163.6% | -289.5% | - | -733.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 0.4% | - | - | - | -73.8% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -96.2% | -90.1% | 11.8% | 27.9% | 9.7% | 22.6% | -6.9% | 6.0% | 9743.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$751.10M totalMedicare$519.83M · 69.2%
Medicaid$105.89M · 14.1%
Government Value$67.71M · 9.0%
Product And Service Other$57.67M · 7.7%
Peer comparison
Same SIC group: Services-Nursing & Personal Care Facilities
Comparing CareMax against the 5 most active filers in the same SIC group.